Analysis of SARS-CoV-2 Variant-Specific Serum Antibodies Post-Vaccination Utilizing Immortalized Human Hepatocyte-like Cells (HLC) to Assess Development of Protective Immunity

Daniel P Collins, Clifford J Steer
doi: https://doi.org/10.1101/2023.08.08.23293863

Article Information

doi 
https://doi.org/10.1101/2023.08.08.23293863
History 
  • August 13, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Daniel P Collins1,* and
  2. Clifford J Steer2,3
  1. 1CMDG, LLC, Saint Paul, MN, USA
  2. 2Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
  3. 3Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN, USA
  1. ↵*Correspondence: Daniel P. Collins, Ph.D., CMDG, LLC, Saint Paul, MN 55127, USA; Email dc{at}cmdgllc.com
Back to top
Posted August 13, 2023.
Download PDF
Data/Code
Email
Analysis of SARS-CoV-2 Variant-Specific Serum Antibodies Post-Vaccination Utilizing Immortalized Human Hepatocyte-like Cells (HLC) to Assess Development of Protective Immunity
Daniel P Collins, Clifford J Steer
medRxiv 2023.08.08.23293863; doi: https://doi.org/10.1101/2023.08.08.23293863
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area